Skip to content
Search

Latest Stories

Negotiations on CPCF arrangements for 2022/23 begin

The tripartite negotiations to set the arrangements for the Community Pharmacy Contractual Framework (CPCF) in 2022/23 – Year 4 of the five-year CPCF deal – have now begun, the Pharmaceutical Services Negotiating Committee (PSNC) said.

The discussions, beginning ahead of the start of the financial year, are taking place between the PSNC and the Department of Health and Social Care (DHSC) and the NHS England and NHS Improvement (NHSE&I).


It will cover issues related to service, funding and other arrangements for pharmacies in 2022/23, in line with the five-year CPCF deal.

The three entities will also discuss the progress made to date, which has been partly impacted by the Covid-19 pandemic, and the recent joint Annual Review process, where PSNC raised serious concerns around the available capacity within community pharmacy.

The negotiator stated that all parties recognise the contribution of community pharmacies towards the healthcare in the first three years of the five-year CPCF deal.

It added that the PSNC is committed to work to embed community pharmacies, and expand their role within wider NHS systems.

Bharat Patel, PSNC vice-chair and negotiating team member, and an independent community pharmacy contractor, said: “As we approach the end of Year 3 of the five-year CPCF arrangements, many contractors find themselves in an extremely difficult situation trying to balance spiralling costs, capacity pressures and the increasing workforce issues. Some of the immediate pressures of Covid-19 may appear to have gone away, but like most of the health service, pharmacies are not feeling any relief.

“PSNC’s Negotiating Team worked hard through the recent Annual Review process to show government and the NHS the reality facing community pharmacies. We set out our serious concerns around the capacity available in the absence of planned efficiency gains, and about the unsustainable efficiencies that the past two years have required of the sector.

“We have been clear that without the injection of additional funding, capacity is unlikely to be able to grow, particularly at a time of accelerated pressures on staffing.

He noted that though the Spending Review showed a funding uplift is not possible, but “we must continue to make a strong case for investment in the sector, and to seek fair funding for the walk-in advice that so many people are relying on from pharmacies.

“We are actively gathering evidence as we begin what we expect, once again, to be very challenging discussions.”

Andrew Lane Andrew Lane, chair, NPA

Commenting on the funding needs, the National Pharmacy Association (NPA) chair Andrew Lane, said: “We understand why this will be a challenging round of negotiations, but all parties should proceed on the basis that pharmacies provide vital services and deliver for the NHS in a cost-effective way.

“It’s time to end the years of underfunding in England and instead invest in pharmacies to meet the growing healthcare needs of the population.”

The PSNC informed that these negotiations will remain confidential but it will update contractors on the outcomes of these discussions.

More For You

US-UK pharmaceutical trade concerns as Liberal Democrat MPs urge protection from Trump tariffs.

UK prime minster Sir Keir Starmer with US president Donald Trump

Pic credit: Getty images

Pharma sector needs protecting from Trump tariffs, warn MPs

A group of Liberal Democrat MPs have written to health secretary Wes Streeting urging him to protect the pharmaceutical industry from US president Donald Trump’s trade war.

The five ministers from Oxfordshire, Olly Glover, Layla Moran, Calum Miller, Charlie Maynard, and Freddie van Mierlo, have warned that Trump’s campaign to raise tariffs has already led to “catastrophic damage”.

Keep ReadingShow less
Pharmacist handing medicine to patient, NHS prescription cost freeze debate

Prescription charge will remain at £9.90

Pic credit: iStock

NPA calls for end to prescription charge after freeze announcement

The National Pharmacy Association (NPA) has asked for prescription charges to be completely removed despite the government announcing today that the charge will be frozen for the first time in three years.

Patients will continue paying £9.90 to collect their medication from a pharmacy.

Keep ReadingShow less
RPS launches new prescribing development programme for pharmacists

From 2026, every newly qualified pharmacist will be an independent prescriber

gettyimages

RPS unveils new training programme to enhance pharmacists’ prescribing skills

The Royal Pharmaceutical Society (RPS) has announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

The initiative comes ahead of the NHS mandate that every newly qualified pharmacist will be an independent prescriber by 2026 — a change set to transform the future of pharmacy practice.

Keep ReadingShow less
Varenicline promotes nicotine vaping cessation in young people

Researchers warn that e-cigarette use can increase risk for nicotine addiction,uptake of combusted tobacco and other substance use.

gettyimages

Anti-smoking pill varenicline may help young people quit vaping, new study suggests

Varenicline — a daily pill already offered through NHS Stop Smoking Services — could also support young people in quitting vaping, new research has suggested.

The medication, proven to be more effective than nicotine replacement gums or patches for smoking cessation, was shown to significantly boost vaping abstinence when combined with behavioural counselling in adolescents and young adults.

Keep ReadingShow less
Relying on blue inhalers alone can worsen asthma symptoms, warns MHRA

Patients are advised to use their preventer inhaler regularly, even if their asthma feels under control.

Pic credit: gettyimages

Overuse of blue inhalers can increase risk of severe asthma attacks, warns MHRA

The Medicines and Healthcare products Regulatory Agency (MHRA) is reminding asthma patients to use their preventer (anti-inflammatory) inhalers regularly as prescribed, rather than relying solely on their blue inhalers, also referred to as reliever inhalers.

“Without regular use of a preventer inhaler, symptoms could worsen and increase the risk of severe asthma attacks,” the MHRA warned.

Keep ReadingShow less